Constitution of a system of microarray CGH analysis for wide-screening and a research for genes responsible for hepatocellular carcinoma

HBV DNA整合在人DNA的随机位点，MLL 2基因是整合的靶点。本研究采用RT-PCR方法检测了肝细胞癌患者癌组织和癌旁组织中高迁移率族蛋白A_2（HMGA_2）的表达和变化。在三分之一的癌组织中发现表达，并且在低分化癌中的患病率增加。在低分化肝癌中这种交替也增加。结果表明，HMGA 2的表达和变化与肝癌的发生发展有关，血清中高浓度的细胞角蛋白19片段（CK-19片段）（CYFRA 21-1）常在主要门静脉中肿瘤直径大于5 cm的癌栓患者中检测到，CYFRA 21\1因其灵敏度低而不是肝细胞癌的有用诊断工具。在因肝细胞癌而接受肝切除术的患者中，对干扰素治疗有反应的患者的结果优于对干扰素治疗无反应或缺乏治疗的患者。干扰素治疗可以改善术后预后，因为它可以抑制肝硬化的复发和预防预后，特别是当干扰素治疗控制了活动性肝炎时。

HBV DNA was integrated at random sites of human DNA, and the MLL2 gene was cone of the targets for integration. Our results suggest that HBV DNA might modulate human genes near integration sites, followed by integration site - specific expression of such genes during hepatocarcinogenesis.The expression and alternation of high mobility group A2 (HMGA2) were investigated by RT-PCR using cancerous tissues and noncancerous tissues in patients with hepatocellular carcinoma. The expression was found in one-third of cancerous tissues and the prevalence increased in less differentiated carcinoma. The alternation also increased in poorly differentiated hepatocellular carcinoma. The results indicate the expression and alternation of HMGA2 correlated with the development of hepatocellular carcinoma.Although high concentration of serum cytokeratin-19 fragment (CYFRA 21-1) were often detected in patients with a tumor diameter greater than 5 cm of tumor thrombus in the major portal vein, CYFRA 21\1 is not a useful diagnostic tool for hepatocellular carcinoma because of its low sensitivity.In patients who underwent liver resection for hepatocellular carcinoma, the results were superior in patients who respond interferon therapy than in patients who did not respond the therapy or who lacks the therapy. Interferon therapy can improve postoperative outcomes because of suppression of recurrence and preventing prognosis of cirrhosis, especially when interferon therapy has controlled their active hepatitis.